Johnson & Johnson $JNJ Stake Reduced by Schwarz Dygos Wheeler Investment Advisors LLC

Schwarz Dygos Wheeler Investment Advisors LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,087 shares of the company’s stock after selling 536 shares during the quarter. Schwarz Dygos Wheeler Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,999,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Pandora Wealth Inc. acquired a new position in Johnson & Johnson in the 1st quarter worth $65,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $195.19 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $196.00. The stock has a market capitalization of $470.27 billion, a price-to-earnings ratio of 18.84, a PEG ratio of 2.19 and a beta of 0.38. The firm’s 50-day moving average price is $185.46 and its two-hundred day moving average price is $169.66.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s payout ratio is 50.19%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $206.00 in a report on Tuesday, September 23rd. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Bank of America increased their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $200.52.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.